- Home
- YDDL vs DMAC Comparison
YDDL vs DMAC Comparison
Compare YDDL & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YDDL
- DMAC
- Stock Information
- Founded
- YDDL 2014
- DMAC 2000
- Country
- YDDL Philippines
- DMAC United States
- Employees
- YDDL N/A
- DMAC N/A
- Industry
- YDDL Industrial Specialties
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- YDDL Consumer Discretionary
- DMAC Health Care
- Exchange
- YDDL Nasdaq
- DMAC Nasdaq
- Market Cap
- YDDL 295.4M
- DMAC 310.1M
- IPO Year
- YDDL 2025
- DMAC N/A
- Fundamental
- Price
- YDDL $4.90
- DMAC $7.13
- Analyst Decision
- YDDL
- DMAC Strong Buy
- Analyst Count
- YDDL 0
- DMAC 3
- Target Price
- YDDL N/A
- DMAC $12.33
- AVG Volume (30 Days)
- YDDL 6.2M
- DMAC 302.5K
- Earning Date
- YDDL 01-01-0001
- DMAC 11-12-2025
- Dividend Yield
- YDDL N/A
- DMAC N/A
- EPS Growth
- YDDL 16.34
- DMAC N/A
- EPS
- YDDL 0.12
- DMAC N/A
- Revenue
- YDDL $53,463,785.00
- DMAC N/A
- Revenue This Year
- YDDL N/A
- DMAC N/A
- Revenue Next Year
- YDDL N/A
- DMAC N/A
- P/E Ratio
- YDDL $52.67
- DMAC N/A
- Revenue Growth
- YDDL 29.55
- DMAC N/A
- 52 Week Low
- YDDL $4.60
- DMAC $3.19
- 52 Week High
- YDDL $8.89
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- YDDL N/A
- DMAC 60.80
- Support Level
- YDDL N/A
- DMAC $6.56
- Resistance Level
- YDDL N/A
- DMAC $7.12
- Average True Range (ATR)
- YDDL 0.00
- DMAC 0.29
- MACD
- YDDL 0.00
- DMAC -0.05
- Stochastic Oscillator
- YDDL 0.00
- DMAC 92.19
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.